Nanoassemblies from amphiphilic cytarabine prodrug for leukemia targeted therapy

Journal of Colloid and Interface Science

Volumn 487, Issue , 2017, Pages 239-249

  Liu, Jing ^a   Zhao, Dujuan ^a   He, Wenxiu ^a   Zhang, Huiyuan ^a   Li, Zhonghao ^a   Luan, Yuxia ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Amphiphilic small molecular prodrug; Cytarabine; Folic acid; Leukemia therapy; Nanoassembly

Indexed keywords

BODY FLUIDS; CELLS; CYTOLOGY; FATTY ACIDS; ORGANIC ACIDS;

CYTARABINE; FOLIC ACIDS; LEUKEMIA THERAPIES; NANO-ASSEMBLIES; PRODRUGS;

DISEASES;

AMPHOPHILE; BOVINE SERUM ALBUMIN; CYTARABINE; FOLATE RECEPTOR; FOLIC ACID; PRODRUG; ANTINEOPLASTIC ANTIMETABOLITE; DRUG CARRIER; FOLATE RECEPTOR 1; HEXANOIC ACID; HEXANOIC ACID DERIVATIVE; NANOCONJUGATE; PROTEIN BINDING;

A549 CELL LINE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; COVALENT BOND; DRUG EFFICACY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HEMOLYSIS; HUMAN; HUMAN CELL; HYDRODYNAMICS; IC50; IN VITRO STUDY; K562 CELL LINE; LEUKEMIA; MOLECULARLY TARGETED THERAPY; MTT ASSAY; PARTICLE SIZE; PLASMA HALF LIFE; PRIORITY JOURNAL; SURFACE PROPERTY; ZETA POTENTIAL; ANIMAL; BOVINE; CHEMISTRY; DRUG FORMULATION; GENE EXPRESSION; GENETICS; K-562 CELL LINE; METABOLISM; SYNTHESIS; TRANSPORT AT THE CELLULAR LEVEL; ULTRASTRUCTURE;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CAPROATES; CATTLE; CYTARABINE; DRUG CARRIERS; DRUG COMPOUNDING; FOLATE RECEPTOR 1; FOLIC ACID; GENE EXPRESSION; HUMANS; INHIBITORY CONCENTRATION 50; K562 CELLS; MOLECULAR TARGETED THERAPY; NANOCONJUGATES; PRODRUGS; PROTEIN BINDING; SERUM ALBUMIN, BOVINE;

EID: 84992316141     PISSN: 00219797     EISSN: 10957103     Source Type: Journal    
DOI: 10.1016/j.jcis.2016.10.041     Document Type: Article

References (47)

1. [1] Estey, E., Othus, M., Lee, S.J., Appelbaum, F.R., Gale, R.P., New drug approvals in acute myeloid leukemia: what's the best end point. Leukemia 30 (2016), 521–525.
2. [2] Landry, B., Uludağ, H.G., Plianwong, S., Kucharski, C., Zak, Z., Parmar, M.B., Kutsch, O., Jiang, H., Brandwein, J., Uludağ, H., Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia. J. Control. Release 224 (2016), 8–21.
3. [3] Couvreur, P., Stella, B., Reddy, L.H., Hillaireau, H., Dubernet, C., Desmaële, D., Mouelhi, S.L., Rocco, F., Bosquet, N.D., Clayette, P., Rosilio, V., Marsaud, V., Renoir, J.M., Cattel, L., Squalenoyl nanomedicines as potential therapeutics. Nano Lett. 6 (2006), 2544–2548.
4. [4] Réjiba, S., Reddy, L.H., Bigand, C., Parmentier, C., Couvreur, P., Hajri, A., Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer. Nanomedicine 7 (2011), 841–849.
5. [5] Tang, H., Murphy, C.J., Zhang, B., Shen, Y., Sui, M., Kirk, E.V.A., Feng, X., Murdoch, W.J., Amphiphilic curcumin conjugate-forming nanoparticles as anticancer prodrug and drug carriers: in vitro and in vivo effects. Nanomedicine 5 (2010), 855–865.
6. [6] Shen, Y., Jin, E., Zhang, B., Murphy, C.J., Sui, M., Zhao, J., Wang, J., Tang, J., Fan, M., Kirk, E.V., Murdoch, W.J., Prodrugs forming high drug loading multifunctional nanocapsules for intracellular cancer drug delivery. J. Am. Chem. Soc. 132 (2010), 4259–4265.
7. [7] Luo, C., Sun, J., Sun, B., He, Z., Prodrug-based nanoparticulate drug delivery strategies for cancer therapy. Trends Pharmacol. Sci. 35 (2014), 556–566.
8. [8] Maksimenko, A., Dosio, F., Mougin, J., Ferrero, A., Wack, S., Reddy, L.H., Weyn, A.A., Lepeltier, E., Bourgaux, C., Stella, B., Catte, L., Couvreur, P., A unique squalenoylated and nonpegylated doxorubicin nanomedicine with systemic long-circulating properties and anticancer activity. Proc. Natl. Acad. Sci. USA 111 (2014), E217–E226.
9. [9] Cheetham, A.G., Zhang, P., Lin, Y., Lock, L.L., Cui, H., Supramolecular nanostructures formed by anticancer drug assembly. J. Am. Chem. Soc. 135 (2013), 2907–2910.
10. [10] Zhang, H., Wang, J., Mao, W., Huang, J., Wu, X., Shen, Y., Sui, M., Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies. J. Control. Release 166 (2013), 147–158.
11. [11] Chen, J.X., Xu, X.D., Chen, W.H., Zhang, X.Z., Multi-functional envelope-type nanoparticles assembled from amphiphilic peptidic prodrug with improved anti-tumor activity. ACS Appl. Mater. Interfaces 6 (2014), 593–598.
12. [12] Maksimenko, M., Mougin, J., Mura, S., Sliwinski, E., Lepeltier, E., Bourgaux, C., Lepêtre, S., Zouhiri, F., Desmaële, D., Couvreur, P., Polyisoprenoyl gemcitabine conjugates self-Assemble as nanoparticles, useful for cancer therapy. Cancer Lett. 334 (2013), 346–353.
13. [13] Mura, S., Zouhiri, F., Lerondel, S., Maksimenko, A., Mougin, J., Gueutin, C., Brambilla, D., Caron, J., Sliwinski, E., Lepape, A., Desmaële, D., Couvreur, P., Novel isoprenoyl nanoassembled prodrug for paclitaxel delivery. Bioconjug. Chem. 24 (2013), 1840–1849.
14. [14] Danhier, F., Feron, O., Préat, V., To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 148 (2010), 135–146.
15. [15] Lu, Y., Sega, E., Leamon, C.P., Low, P.S., Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential. Adv. Drug Delivery Rev. 56 (2004), 1161–1176.
16. [16] Moore, N.W., Kuhl, T.L., The role of flexible tethers in multiple ligand-receptor bond formation between curved surfaces. Biophys. J. 91 (2006), 1675–1687.
17. [17] Ross, J.F., Wang, H., Behm, F.G., Mathew, P., Wu, M., Booth, R., Ratnam, M., Folate receptor type β is a neutrophilic lineage marker and is differentially expressed in myeloid leukemia. Cancer 85 (1999), 348–357.
18. [18] Lynn, R.C., Poussin, M., Kalota, A., Feng, Y., Low, P.S., Dimitrov, D.S., Powell, D.J. Jr., Targeting of folate receptor-beta on acute myeloid leukemia blasts with chimeric antigen receptor expressing T cells. Blood 125 (2015), 3466–3476.
19. [19] Shi, Y., Su, Z., Li, S., Chen, Y., Chen, X., Xiao, Y., Sun, M., Ping, M., Multistep targeted nano drug delivery system aiming at leukemic stem cells and minimal residual disease. Mol. Pharm. 10 (2013), 2479–2489.
20. [20] Pan, X.Q., Zheng, X., Shi, G., Wang, H., Ratnam, M., Lee, R.J., Strategy for the treatment of acute myelogenous leukemia based on folate receptor β–targeted liposomal doxorubicin combined with receptor induction using all-trans retinoic acid. Blood 100 (2002), 594–602.
21. [21] Löwenberg, B., Downing, J.R., Burnet, A., Acute myeloid leukemia. N. Engl. J. Med. 341 (1999), 1051–1062.
22. [22] Furth, J.J., Cohen, S., Inhibition of mammalian DNA polymerase by the 5′-triphosphate of 1-beta-D arabinofuranosylcytosine and 5′-triphosphate of 9-β-D-arabinofuranosyladenine. Cancer Res. 28 (1968), 2061–2067.
23. [23] Major, P.P., Egan, E.M., Beardsley, G.P., Minden, M.D., Kufe, D.W., Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc. Natl. Acad. Sci. USA 78 (1981), 3235–3239.
24. [24] Grant, S., Ara-C: cellular and molecular pharmacology. Adv. Cancer Res. 72 (1997), 197–233.
25. [25] Momparler, R.L., A model for the chemotherapy of acute leukemia with 1-β-D-arabinofuranosylcytosine. Cancer Res. 34 (1974), 1775–1787.
26. [26] Liu, J., Ma, N., Zhao, D., Li, Z., Luan, Y., Spiral assembly of amphiphilic cytarabine prodrug assisted by probe sonication: enhanced therapy index for leukemia. Colloid Surf. B 136 (2015), 918–927.
27. [27] Liu, J., Liu, J., Zhao, D., Ma, N., Luan, Y., Highly enhanced leukemia therapy and oral bioavailability from a novel amphiphilic prodrug of cytarabine. RSC Adv. 6 (2016), 35991–35999.
28. [28] Lomova, M.V., Brichkina, A.I., Kiryukhin, M.V., Vasina, E.N., Pavlov, A.M., Gorin, D.A., Sukhorukov, G.B., Antipina, M.N., Multilayer capsules of bovine serum albumin and tannic acid for controlled release by enzymatic degradation. ACS Appl. Mater. Interfaces 7 (2015), 11732–11740.
29. [29] Mody, K.T., Popat, A., Mahony, D., Cavallaro, A.S., Yu, C., Mitter, N., Mesoporous silica nanoparticles as antigen carriers and adjuvants for vaccine delivery. Nanoscale 5 (2013), 5167–5179.
30. [30] Suthiwangcharoen, N., Li, T., Wu, L., Reno, H.B., Thompson, P., Wang, Q., Facile co-Assembly process to generate core−shell nanoparticles with functional protein corona. Biomacromolecules 15 (2014), 948–956.
31. [31] Du, L., Lian, Y., Jin, Y., Self-assembly of N-acyl derivatives of gemcitabine at the air/water interface and the formation of nanoscale structures in water. Colloid Surf. A – Physicochem. Eng. Aspects 393 (2012), 60–65.
32. [32] Tao, X., Wang, J., Wang, J., Feng, Q., Gao, S., Zhang, L., Zhang, Q., Enhanced anticancer activity of gemcitabine coupling with conjugated linoleic acid against human breast cancer in vitro and in vivo. Eur. J. Pharm. Biopharm. 82 (2012), 401–409.
33. [33] Lepeltier, E., Bourgaux, C., Couvreur, P., Nanoprecipitation and the “ouzo effect”: application to drug delivery devices. Adv. Drug Delivery Rev. 71 (2014), 86–97.
34. 2 nanoparticle-lipid interactions. J. Colloid Interface Sci. 473 (2016), 75–83.
35. [35] Qi, L., Guo, Y., Luan, J., Zhang, D., Zhao, Z., Luan, Y., Folate-modified bexarotene-loaded bovine serum albumin nanoparticles as a promising tumor targeting delivery system. J. Mater. Chem. B 2 (2014), 8361–8371.
36. [36] Li, M., Song, W., Tang, Z., Lv, S., Lin, L., Sun, H., Li, Q., Yang, Y., Hong, H., Chen, X., Nanoscaled poly (L-glutamic acid)/doxorubicin-amphiphile complex as pH-responsive drug delivery system for effective treatment of nonsmall cell lung cancer. ACS Appl. Mater. Interfaces 5 (2013), 1781–1792.
37. [37] Li, F., Liu, J., Shi, J., Luan, Y., Synthesis and biological evaluation of a fatty acyl di-cytarabine prodrug. RSC Adv. 5 (2015), 25382–25388.
38. [38] Wang, Y., Liu, D., Zheng, Q., Zhao, Q., Zhang, H., Ma, Y., Fallon, J.K., Fu, Q., Haynes, M.T., Lin, G., Zhang, R., Wang, D., Yang, X., Zhao, L., He, Z., Liu, F., Disulfide bond bridge insertion turns hydrophobic anticancer prodrugs into self-assembled nanomedicines. Nano Lett. 14 (2014), 5577–5583.
39. [39] Krishnamoorthy, K., Veerapandian, M., Yun, K., Kim, S.J., The chemical and structural analysis of graphene oxide with different degrees of oxidation. Carbon 53 (2013), 38–49.
40. [40] Kwon, G., Naito, M., Yokoyama, M., Okano, T., Sakurai, Y., Kataoka, K., Micelles based on AB block copolymers of poly (ethylene oxide) and poly (β-benzyl L-aspartate). Langmuir 9 (1993), 945–949.
41. [41] Zhou, J., Romero, G., Rojas, E., Ma, L., Moya, S., Gao, C.J., Layer by layer chitosan/alginate coatings on poly (lactide-co-glycolide) nanoparticles for antifouling protection and folic acid binding to achieve selective cell targeting. Colloid Interface Sci. 345 (2010), 241–247.
42. [42] Hong, S., Leroueil, P.R., Janus, E.K., Peters, J.L., Kober, M.M., Islam, M.T., Orr, B.G., Baker, J.R., Holl, M.M.B., Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug. Chem. 17 (2006), 728–734.
43. [43] Liu, H.M., Wu, S.H., Lu, C.W., Yao, M., Hsiao, J.K., Hung, Y., Lin, Y.S., Mou, C.Y., Yang, C.S., Huang, D.M., Chen, Y.C., Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells. Small 4 (2008), 619–626.
44. [44] Yang, Y., Yan, X., Cui, Y., He, Q., Li, D., Wang, A., Fei, J., Li, J., Preparation of polymer-coated mesoporous silica nanoparticles used for cellular imaging by a ‘‘graft-from’’ method. J. Mater. Chem. 18 (2008), 5731–5737.
45. [45] Bildstein, L., Dubernet, C., Couvreur, P., Prodrug-based intracellular delivery of anticancer agents. Adv. Drug Delivery Rev. 63 (2011), 3–23.
46. [46] Sarpietro, M.G., Ottimo, S., Giuffrida, M.C., Rocco, F., Ceruti, M., Castelli, F., Synthesis of n-squalenoyl cytarabine and evaluation of its affinity with phospholipid bilayers and monolayers. Int. J. Pharm. 385 (2010), 113–142.
47. [47] Cheon, E.P., Hong, J.H., Han, H.K., Enhanced cellular uptake of Ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells. J. Pharm. Pharmacol. 58 (2006), 927–932.